Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

13.99
+0.36002.64%
Volume:305.85K
Turnover:4.25M
Market Cap:772.87M
PE:-5.07
High:14.20
Open:13.65
Low:13.55
Close:13.63
52wk High:16.93
52wk Low:6.47
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.70
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:1.90
PE(LYR):-5.78

Loading ...

BRIEF-4D Molecular Therapeutics Q1 Net Income USD -68.76 Million Vs. IBES Estimate USD -62.6 Million

Reuters
·
May 08

4D Molecular Therapeutics Inc expected to post a loss of 99 cents a share - Earnings Preview

Reuters
·
May 05

4D Molecular Therapeutics to present at BofA Securities Healthcare Conference

Reuters
·
May 04

4D Molecular Therapeutics announces annual shareholder meeting

Reuters
·
Apr 29

4D Molecular Therapeutics grants 67,600 RSUs under 2025 employment inducement plan

Reuters
·
Apr 18

4D Molecular price target lowered to $23 from $45 at Evercore ISI

TIPRANKS
·
Apr 13

4D Molecular Therapeutics Consolidates Financial Leadership Under New Role

TIPRANKS
·
Mar 31

4D Molecular Therapeutics names CFO Kristian Humer principal accounting officer

Reuters
·
Mar 31

4D Molecular Therapeutics Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 31

U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan

Reuters
·
Mar 30

4D Molecular Therapeutics VP Finance and Controller Ashoo Gupta disposes of USD 3,356 in common shares

Reuters
·
Mar 25

Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies

TIPRANKS
·
Mar 20

4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Mar 19

4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald

TIPRANKS
·
Mar 19

RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Mar 19

Chardan Capital Remains a Buy on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Mar 19

4D Molecular Therapeutics publishes corporate presentation on 4D-150 retinal gene therapy program

Reuters
·
Mar 19

4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.82) Estimate, Sales $85.090M Beat $21.817M Estimate

Benzinga Earnings
·
Mar 19

4D Molecular Therapeutics FY 2025 R&D expenses rise 39% to USD 196 million, net loss narrows 13% to USD 140 million

Reuters
·
Mar 19

Press Release: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Dow Jones
·
Mar 19